WallStSmart
DARE

Dare Bioscience Inc

NASDAQ: DARE · HEALTHCARE · BIOTECHNOLOGY

$2.28
+8.57% today

Updated 2026-04-30

Market cap
$30.72M
P/E ratio
P/S ratio
29.82x
EPS (TTM)
$-1.20
Dividend yield
52W range
$1 – $3
Volume
0.4M

Dare Bioscience Inc (DARE) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+44.9%
Last 4 quarters
Revenue YoY growth
-1708.4%
Most recent quarter
EPS YoY growth
+84.5%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+7.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+21.2%
2026-03-27
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-27$-0.10+76.0%$1.51$1.83+21.2%
2025-11-13$-0.28-1500.0%$1.98$1.86-6.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.42$-0.10+76.0%$1.02M-1708.4%
2025-09-30$0.02$-0.28-1500.0%$2262.00-94.6%
2025-06-30$0.03$-0.45-1600.0%$-21172.00-194.4%
2025-03-31$-0.58$-0.50+13.8%$25427.00+173.3%
2024-12-31$-0.63$-0.65-2.6%$-63647.00-103.5%
2024-09-30$-0.73$-0.55+24.7%$41691.00-95.8%
2024-06-30$0.02$-0.88-4500.0%$22438.00
2024-03-31$-0.06$-0.07-16.7%$9302.00
2023-12-31$-0.10$-0.06+40.0%$1.81M
2023-09-30$-0.10$-0.09+10.0%$1.00M
2023-06-30$-0.10$-0.10+0.0%
2023-03-31$-0.10$-0.09+10.0%

Frequently asked questions

Has Dare Bioscience Inc beaten earnings estimates?
Dare Bioscience Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +44.9% over the last 2 quarters.
How does DARE stock react to earnings?
DARE stock has moved an average of +7.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Dare Bioscience Inc's revenue growth rate?
Dare Bioscience Inc reported year-over-year revenue growth of -1708.4% in its most recent quarter, with EPS growing +84.5% year-over-year.